Nippon Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 28-06-2024
- Paid Up Capital ₹ 0.50 M
as on 28-06-2024
- Company Age 28 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.10 M
as on 28-06-2024
- Revenue 28.41%
(FY 2021)
- Profit 16.09%
(FY 2021)
- Ebitda 141.33%
(FY 2021)
- Net Worth -2.20%
(FY 2021)
- Total Assets -9.49%
(FY 2021)
About Nippon Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹6.10 M.
Mridula Gupta and Damini Gupta serve as directors at the Company.
- CIN/LLPIN
U24232RJ1996PTC012495
- Company No.
012495
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Aug 1996
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- LocationJaipur, Rajasthan
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nippon Life Sciences Private Limited offer?
Nippon Life Sciences Private Limited offers a wide range of products and services, including Common Disease Medicines, Hair Growth Medicine, Nutraceuticals & Dietary Supplements, Fitness Supplements, Allopathic Cough Syrup, Multivitamin Syrup & Drops, Vitamin Tablets & Capsules, Flavours & Aromatics, Food Acidulant, Pharmaceutical Tablets.
Who are the key members and board of directors at Nippon Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Damini Gupta  | Director | 27-Sep-2016 | Current |
| Mridula Gupta | Director | 30-Sep-2014 | Current |
Financial Performance of Nippon Life Sciences.
Nippon Life Sciences Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 28.41% increase. The company also saw a substantial improvement in profitability, with a 16.09% increase in profit. The company's net worth dipped by a decrease of 2.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nippon Life Sciences?
In 2021, Nippon Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Triveni Arts Private LimitedActive 37 years 8 months
Mridula Gupta and Damini Gupta are mutual person
- Prismm Medicare Private LimitedActive 38 years 3 months
Mridula Gupta and Damini Gupta are mutual person
- Surams Properties Private LimitedActive 38 years 5 months
Mridula Gupta and Damini Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 06 Jan 2022 | ₹0.80 M | Open |
Uco Bank Creation Date: 09 Jun 2020 | ₹0.80 M | Open |
Uco Bank Creation Date: 23 Feb 2017 | ₹4.50 M | Open |
How Many Employees Work at Nippon Life Sciences?
Unlock and access historical data on people associated with Nippon Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nippon Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nippon Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
